Welcome to our dedicated page for Fractyl Health SEC filings (Ticker: GUTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Fractyl Health’s biotech disclosures can feel like dissecting a medical journal. Clinical trial protocols, FDA Breakthrough updates, and detailed R&D expenses sprawl across dense exhibits, leaving even seasoned analysts asking, “How do I find Revita progress or Rejuva spend in this 10-K?� If you have typed “Fractyl Health SEC filings explained simply� or hunted for “Fractyl Health insider trading Form 4 transactions,� you know the challenge.
Stock Titan turns that complexity into clarity. Our AI parses every line of a “Fractyl Health annual report 10-K simplified,� highlights pivotal pipeline milestones in each “Fractyl Health quarterly earnings report 10-Q filing,� and flags “Fractyl Health 8-K material events explained� within minutes of hitting EDGAR. Interactive summaries connect R&D footnotes to cash-runway tables, while real-time alerts surface “Fractyl Health Form 4 insider transactions real-time� so you can monitor executive conviction the moment it is disclosed. Need quick context for dilution risk before a financing? Our platform delivers “Fractyl Health earnings report filing analysis� without the jargon.
Dig deeper into biotech-specific questions investors actually ask. Track “Fractyl Health executive stock transactions Form 4� alongside trial-stage spending to gauge confidence. Compare GLP-1 competitive disclosures across filings, or review the “Fractyl Health proxy statement executive compensation� section to see how milestone payments align with shareholder value. Whether you are “understanding Fractyl Health SEC documents with AI� for the first time or refining a valuation model, our comprehensive coverage�10-K, 10-Q, 8-K, S-1, and more—keeps you ahead with expert, AI-powered insight and real-time data.
Arteris, Inc. (AIP) Form 144 filing: insider entities led by K. Charles Janac intend to sell 94,245 common shares on or about 08/05/2025 through Morgan Stanley Smith Barney. At the stated price this equals $890,615.25 and represents roughly 0.22 % of the 41,977,728 shares outstanding.
The shares were originally acquired on 06/16/2014 in a private, cash-paid transaction with the issuer. The filer affirms no undisclosed adverse information.
Recent activity: Over the last three months the same account sold 43,557 shares across six Rule 10b5-1 trades, generating $410,078.18 in gross proceeds (largest block: 18,620 shares on 06/27/2025).
- No operational or earnings data is included; the document is solely a notice of proposed insider sales.
Fractyl Health (NASDAQ: GUTS) announced positive 3-month data from the REVEAL-1 cohort of its REMAIN-1 pivotal study, showing promising results for weight management after GLP-1 discontinuation:
- 12 out of 13 participants maintained or lost weight after stopping GLP-1 treatment and receiving a single Revita procedure
- 6 participants achieved additional weight loss
- Median weight remained stable through 3 months, contrasting with typical 5-6% rebound in studies like SURMOUNT-4
- Procedure demonstrated strong safety profile with no serious adverse effects
Additionally, the company revealed new preclinical data for its Rejuva® Smart GLP-1� pancreatic gene therapy platform. A single dose prevented obesity and hyperglycemia in animals on high-fat diets. The company expects REMAIN-1 Midpoint Cohort data in Q3 2025 and RJVA-001 preliminary clinical data in 2026.
FAQ
What is the current stock price of Fractyl Health (GUTS)?
What is the market cap of Fractyl Health (GUTS)?
What is the primary focus of Fractyl Health?
How does Fractyl Health’s Revita procedure work?
What distinguishes the Rejuva platform?
How does Fractyl Health address weight maintenance after GLP-1 therapy?
What regulatory achievements has Fractyl Health accomplished?
Who can benefit from Fractyl Health's therapies?
How does the company ensure its research and therapies are scientifically robust?
What potential advantages do Fractyl Health's treatments offer over traditional therapies?
